The Latest

  • COUR Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Myasthenia Gravis
  • Skip to primary navigation
  • Skip to main content
  • Skip to footer
COUR Pharmaceuticals Logo

COUR Pharmaceuticals

  • Our Company
    • Leadership
    • Advisors
    • Partners
    • Contact
  • Our Technology
    • Pipeline
    • Autoimmune Diseases
    • Allergies
    • Rare Diseases
    • Gene Therapy
  • Our Clinical Trials
  • Publications & Media
    • Press Releases
    • Publications
  • Careers

Advisors

COUR’s medical advisors bring unique medical perspectives and expertise to drive the strategic direction and success for potentially life-changing technology.

Kari Nadeau, MD, PHD
Kari Nadeau, MD, PHD Featured

Kari Nadeau, MD, PHD

Stanford University

Ciarán P. Kelly, MD
Ciarán P. Kelly, MD Featured

Ciarán P. Kelly, MD

Harvard Medical School

John Fung, MD, PhD
John Fung, MD, PhD Featured

John Fung, MD, PhD

University of Chicago

M. Eric Gershwin, MD, MACP, MACR
M. Eric Gershwin, MD, MACP, MACR Featured

M. Eric Gershwin, MD, MACP, MACR

University of California, Davis

Stephen D. Miller, PHD
Stephen D. Miller, PHD Featured

Stephen D. Miller, PHD

Northwestern University

Lonnie D. Shea, PHD
Lonnie D. Shea, PHD Featured

Lonnie D. Shea, PHD

University of Michigan

Footer

COUR Pharmaceuticals Logo
  • Our Company
  • Our Technology
  • Our Partners
  • Press
  • Careers

©

2023

COUR Pharmaceuticals.
All Rights Reserved.

Privacy Policy • Terms of Use

Back to Top